Putting Big Pharma In Perspective
March 17, 2015 4:00pm by Barry Ritholtz
This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client. References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. The Compound Media, Inc., an affiliate of Ritholtz Wealth Management, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. Investments in securities involve the risk of loss. For additional advertisement disclaimers see here: https://www.ritholtzwealth.com/advertising-disclaimers Please see disclosures here: https://ritholtzwealth.com/blog-disclosures/
What's been said:
Discussions found on the web:Posted Under
Previous Post
Separate Trend from CycleNext Post
Masters in Business: Brad Katsuyama
On my trip thru the stent business I discovered that J&J is basically a marketing company. They outsourced much of the scientific legwork and were first in and first out. The process/timing was akin to a generic drug introduction, with an exclusivity window.
How much should they spend?
J&J has a large consumer products business that sells everything from Band Aids to Neutrogena as well as OTC meds with Tylenol. They also have a medical device business. Their Pharma segment was 34.5% of their revenue last year.
Typo 43.5% of sales for Pharma.
“How much should they spend?”
I don’t know but when they justify higher prices in the US based on their enormous research costs the above indicates that that arguments is 50%-60% BS.
Is it any wonder why the US is so over medicated yet unhealthy?
Barry, do you still trust everything that Big Pharma* and their lackeys tell you about vaccinations?
—-
* Big Pharma includes doctors, marketers, FDA revolving door bureaucrats on their payroll; does not include pure “Scientists”
You are confusing Jonah Salk with Bernie Ebbers.
Its pretty obvious to anyone who reads Ritholtz that he does not trust corporate entities at all,but does seem to have some faith in scientists, doctors, and researchers.
Corporate entities seeking a profit is very different than the people who created the vaccines